Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis (3-component)
- Development stage
- Phase 3
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine developed by CanSino Biologics Inc. for the prevention of diphtheria, tetanus, and pertussis in infants and children. This specific formulation utilizes a three-component acellular pertussis (DTcP) technology, which includes purified pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). Unlike older co-purified acellular vaccines, the three-component approach allows for precise control over the concentration of each antigen, potentially improving consistency and immunogenicity. The vaccine is currently in Phase III clinical trials as a standalone product and serves as a core component of CanSino's hexavalent DTcP-Hib-MCV4 vaccine candidate, which is in Phase I trials.
- Brand names
- InfanrixDaptacelTripediaAcel-ImuneCertiva
- Other names
- Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-PertussisDTcP vaccine
02
Targets
PRN (Pertactin)Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis (3-component).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis (3-component).